The proportion of APP duplication carriers exhibiting CAA according to Boston-imaging criteria [18] (except the age criterion) remains unknown and studies on AD cerebrospinal fluid (CSF) biomarkers are still required. The gene discussed is APP; the disease is Alzheimer disease.